A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia

Visentin, Andrea; Deodato, Marina; Mauro, Francesca Romana; Autore, Francesco; Reda, Gianluigi; Vitale, Candida; Molica, Stefano; Rigolin, Gian Matteo; Cesini, Laura; Tedeschi, Alessandra; Laurenti, Luca; Cassin, Ramona; Coscia, Marta; Cuneo, Antonio; Foà, Robin; Semenzato, Gianpietro; Trentin, Livio

doi:10.1002/hon.2655

Cited by 16 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 19 patients, 15 had a sensory or sensory‐motor axonal neuropathy, one had a multiple mononeuropathy, and 3 fulfilled the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) clinical and neurophysiological criteria of CIDP 66 . In our sample, neuropathy was more common in subjects with unfavorable prognostic markers and concomitant monoclonal proteins 67 …”

Section: Non‐hodgkin Lymphoma‐related Peripheral Neuropathiesmentioning

confidence: 68%

From pathogenesis to personalized treatments of neuropathies in hematological malignancies

Briani

Visentin

Cerri³

et al. 2020

J Peripheral Nervous Sys

Self Cite

View full text Add to dashboard Cite

The peripheral nervous system may be involved at any stage in the course of several hematological diseases, the most common being monoclonal gammopathies (of undetermined significance or malignant) or lymphomas. The underlying pathogenic mechanisms are different and therapies aim at targeting the dangerous either B‐cell or plasma cell clones. Recently, high‐throughput technologies, and next‐generation sequencing have increased our knowledge of hematological diseases pathogenesis by the identification of somatic mutation affecting pivotal signaling pathways. Accordingly, new target therapies are used that may also be borrowed for treatment of neuropathies in hematological diseases.

show abstract

Section: Non‐hodgkin Lymphoma‐related Peripheral Neuropathiesmentioning

confidence: 68%

From pathogenesis to personalized treatments of neuropathies in hematological malignancies

Briani

Visentin

Cerri³

et al. 2020

J Peripheral Nervous Sys

Self Cite

View full text Add to dashboard Cite

show abstract

“…Compared with the Shanafelt AF risk score, the Italian AF risk score (categories: 0, 1-2, 3-4, and ≥5) weights older age less heavily (>65 years: 1 point), uses the same weighting for male gender (1 point) and valvular disease (2 points), excludes hypertension, and includes several additional factors that reflect comorbidities relevant to AF in this population (cardiomyopathy: 3 points; hyperthyroidism: 1 point; chronic lung disease: 1 point; diabetes mellitus: 1 point; and severe infections: 1 point). 2,3 Given the potential for greater stratification of higher-risk patients using the Italian score, we agree that a comparative analysis of the Shanafelt AF risk score and the Italian AF risk score using data from our pooled cardiovascular safety analysis of acalabrutinib in patients with CLL is of interest. We are currently assessing these data.…”

mentioning

confidence: 65%

Response to Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”

Brown

2021

haematol

View full text Add to dashboard Cite

show abstract

“… Considerations for the long‐term use of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia patients with an increased risk of cardiovascular disease 93,100‐107 . AF, atrial fibrillation; BTK, Bruton's tyrosine kinase; BTKi, BTK inhibitor; CHA2DS2‐VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65–74 years, sex category score; CLL, chronic lymphocytic leukemia; HAS‐BLED, hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs/alcohol concomitantly …”

Section: Second‐line Treatment Options For R/r Cllmentioning

confidence: 99%

Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management

Eyre

Hori

Munir

2021

Hematological Oncology

View full text Add to dashboard Cite

With the advent of targeted therapies for chronic lymphocytic leukemia (CLL), treatment choice has expanded and patients are living longer. Careful consideration is needed regarding treatment duration and sequence, how best to meet patients' needs, balancing toxicities while improving long-term survival and maximizing depth of response. This review addresses these considerations and discusses current targeted treatment dilemmas. Targeted therapies have dramatically transformed the CLL treatment landscape. Two treatment paradigms have emerged using B-cell lymphoma 2 inhibitors (BCL2i) and Bruton's tyrosine kinase (BTK): (i) fixed duration and (ii) continuous treatment. The BCL2i venetoclax can attain deep remissions with a fixed-duration approach, resulting in high rates of undetectable minimal residual disease (uMRD) in treatment-naïve and relapsed/refractory (R/R) patients with CLL.BTKis such as ibrutinib and acalabrutinib achieve high objective response rates and long-term disease control, although they rarely attain complete response or uMRD status as monotherapy. Numerous studies are evaluating the clinical utility of BTKi and BCL2i as combination therapies, where deep remissions have been found to occur. MRD status may also be a useful marker for deciding when to stop continuous therapy, and randomized trials on MRD-guided treatment strategies are currently ongoing. The current treatment choice between continuous or fixedduration therapy should be based on comorbidities, risks, preferences, and treatment goals, whilst areas of emerging clinical interest include the potential utility of BTKi-BCL2i combination therapies, as well as an MRD-guided treatment strategies in the future.

show abstract

A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia

Cited by 16 publications

References 10 publications

From pathogenesis to personalized treatments of neuropathies in hematological malignancies

From pathogenesis to personalized treatments of neuropathies in hematological malignancies

Response to Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”

Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management

Contact Info

Product

Resources

About